SGLT2 inhibitors consistently improve clinical outcomes in heart failure, and their effects on lipid metabolism - although modest in magnitude - appear metabolically coherent and aligned with improved substrate utilization, reduced lipotoxicity, and qualitative lipoprotein remodeling. This evidence concerns the gene SLC5A2 and heart failure.